文献速递病毒性肝炎

基于索磷布韦方案获持续病毒学应答后晚期复发与丙肝再感染的鉴别

Late Relapse Versus Hepatitis C Virus Reinfection in Patients With Sustained Virologic Response After Sofosbuvir-Based Therapies.
PubMed 文献 · Clin Infect Dis · 2016-10-12

该研究分析11项来迪派韦-索磷布韦及索磷布韦方案3期临床试验,3004例获持续病毒学应答12周的患者中仅12例出现晚期复发病毒血症;系统发育分析显示58%(7/12)为再感染,5例为病毒学复发。鉴别再感染与复发对评估真实疗效及选择再治疗方案有重要意义。

要点

  • SVR12后晚期复发病毒血症发生率低(12/3004)。
  • 58%(7/12)晚期复发病毒血症实为再感染。
  • 系统发育分析可区分病毒学复发与再感染。

核心结论

  • SVR12后晚期复发病毒血症发生率低,且其中部分为再感染而非病毒学复发。

研究设计与样本

  • 基于11项来迪派韦-索磷布韦及索磷布韦方案3期临床试验,共3004例患者。
  • 对SVR12后随访第24周可检出HCV RNA者行多基因系统发育分析以区分复发与再感染。

主要发现

  • 3004例中仅12例在SVR12后可检出HCV RNA。
  • 12例中11例基线与时复发HCV基因型/亚型相同。
  • 系统发育分析显示58%(7/12)为再感染,5例为病毒学复发。

临床怎么用

  • 对SVR12后晚期复发病毒血症者应行系统发育分析以鉴别再感染与复发。
  • 鉴别再感染与复发有助于评估真实疗效并选择再治疗方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The development of direct-acting antivirals in recent years has dramatically enhanced rates of viral eradication to >90% in patients with chronic hepatitis C virus (HCV) infection. To determine true treatment efficacy and define the most appropriate retreatment, it is important to distinguish virologic relapse from reinfection when patients in whom HCV is eradicated during treatment become infected with a new HCV strain after treatment. METHODS: We investigated the prevalence of late recurrent viremia (patients with sustained virologic response 12 weeks after the end of treatment but detectable HCV RNA at follow-up week 24) and used refined phylogenetic analysis of multiple HCV genes to distinguish virologic relapse from reinfection. RESULTS: Across 11 phase 3 clinical trials of ledipasvir-sofosbuvir (SOF) and SOF, only 12 of 3004 patients had detectable HCV RNA following sustained virologic response 12 weeks after the end of treatment. Of these 12 patients with late recurrent viremia, 11 had the same HCV genotype/subtype at baseline and at recurrence. Phylogenetic analysis demonstrated that 58% (7 of 12) of these patients were successfully treated with the SOF-based regimen, with HCV eradication achieved, but became reinfected with a different HCV strain after treatment. The remaining 5 patients with late recurrent viremia had virologic relapse in which the HCV present at baseline persisted in the liver or another compartment and reemerged in the blood 24 weeks after treatment. CONCLUSIONS: The incidence of late recurrent viremia was low. Distinguishing reinfection from virologic relapse has implications for determining true treatment efficiency and selecting optimal retreatment strategies.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Sarrazin C, Isakov V, Svarovskaia ES, et al. Late Relapse Versus Hepatitis C Virus Reinfection in Patients With Sustained Virologic Response After Sofosbuvir-Based Therapies. Clin Infect Dis. 2016. PMID: 27737953

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。